FRANKFURT, Germany, July 3 /PRNewswire/ -- The organization formerly known as the Pharmaceutical Fine Chemicals business of Clariant is now Archimica -- the world’s leading global fine chemicals business focused solely on commercialization solutions for the pharmaceutical industry. The new business is comprised of virtually all assets and personnel that had previously supported commercial activities for the manufacture of high-tech building blocks, regulatory starting materials, cGMP intermediates and active pharmaceutical ingredients (APIs) for the pharmaceutical industry. Archimica will be headquartered in Frankfurt, Germany, with manufacturing and technology development sites in the United States, the United Kingdom, Germany, France and Italy. Archimica begins operations with sales in excess of $250 million and over 800 employees worldwide.
According to Norbert Dieterich, CEO of Archimica, the business’ new name -- Archimica -- underscores the historical tradition of pharmaceutical development in the organization that stretches back over 40 years to the Archimica organization in northern Italy. “Our predecessor company, Archimica, was one of the world’s premiere manufacturers of APIs dating back to the early 1960s. This tradition of pharmaceutical manufacturing belongs to all of our sites where our facilities and many of our people once were part of pharmaceutical companies,” he said. “Our adoption of the Archimica name communicates the strong focus our business will have on commercialization solutions for the pharmaceutical industry. As a business, we will be faster to react to the needs of this market and 100 percent of our resources will go into making us a better partner for the pharmaceutical companies commercializing new products and developing cost-effective sourcing options for their existing portfolios. As we begin this new era, we are strong, steady and focused on pharmaceuticals.”
Continuity of Operations Emphasized
According to Ralf Pfirmann, Global Business Director, the new Archimica organization will function as it had before in delivering technology and manufacturing options to the pharmaceutical industry. “For the past five years, our Pharmaceutical Fine Chemicals business has been working to implement a strategy to be a premiere supplier for the pharmaceutical industry. Going forward, this will not change. We will have the same excellent personnel working within the same frameworks at all of our global sites. This means that our technology development, our process expertise, our manufacturing excellence and our state-of-the-art regulatory compliance efforts will remain the same,” he said. “It is the special nature of the pharmaceutical industry that shapes the offerings of this business. Today we are not just a chemical business and we are not just a pharmaceutical manufacturing business. We have evolved our business model to create value for the pharmaceutical industry where they need it. Our position as a standalone entity will allow us to focus on developing these distinctive capabilities to better serve the needs of major pharma as we move into the future.”
Publicity contact: Tom Nicolay e-mail: tnicolay@resourceadvantage.com phone: +1 973 882 1313 Marketing contact: Dr. Ralf Pfirmann e-mail: Ralf.Pfirmann@clariant.com phone: +49 6196 757 8520 Communications contact: Clara Normando e-mail: clara.normando@clariant.com phone: +39 06 506 2297
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Archimica
CONTACT: Publicity contact: Tom Nicolay, +1-973-882-1313,tnicolay@resourceadvantage.com; Marketing contact: Dr. Ralf Pfirmann, +496196 757 8520, Ralf.Pfirmann@clariant.com; Communications contact: ClaraNormando, +39 06 506 2297, clara.normando@clariant.com, all for Archimica
